



COMPANY OVERVIEW

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of oncology drug candidates, some of which are based on discoveries made at M.D. Anderson Cancer Center. Our clinical stage drugs are Annamycin, an anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, and WP1066, an immunostimulating STAT3 inhibitor targeting brain tumors, pancreatic cancer and AML. We are also engaged in preclinical development of additional drug candidates, including additional STAT3 inhibitors and compounds targeting the metabolism of tumors.

RECENT NEWS

[Moleculin Announces New Data Discovery Confirming Significant Increase in Potential to Starve Cancerous Tumors](#)

Oct 10 2018, 7:30 AM EDT

[Moleculin's Brain Cancer Drug Candidate Begins Patient Dosing at Clinical Trial Being Conducted at MD Anderson](#)

Sep 13 2018, 7:30 AM EDT

[Moleculin Biotech, Inc. Reports Financial Results for the Second Quarter Ended June 30, 2018](#)

Aug 13 2018, 7:30 AM EDT

STOCK OVERVIEW

Symbol	MBRX
Exchange	Nasdaq
Market Cap	32.8m
Last Price	\$1.21
52-Week Range	\$1.03 - \$3.34

INVESTOR RELATIONS

Lytham Partners, LLC
Joe Dorame
Managing Partner
T: (602) 889-9700

MANAGEMENT TEAM

Walter V. Klemp

Founder, President, Chairman, CEO, and Business Advisory Board Member

Donald Picker, PhD

Chief Scientific Officer

Robert Shepard, MD, FACP

Chief Medical Officer - Hematology

Sandra Silberman, MD, PhD

Chief Medical Officer - New Products

Jonathan P. Foster

Chief Financial Officer

MOLECULIN BIOTECH, INC.

5300 Memorial Drive
Suite 950
Houston, TX 77007
US

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.